Acute Respiratory Disease Associated with Adenovirus Serotype 14 -Four States, 2006-2007
Adenovirus serotype 14 (Ad14) is a rarely reported but emerging serotype of adenovirus that can cause severe and sometimes fatal respiratory illness in patients of all ages, including healthy young adults. In May 2006, an infant in New York aged 12 days died from respiratory illness caused by Ad14. During March-June 2007, a total of 140 additional cases of confirmed Ad14 respiratory illness were identified in clusters of patients in Oregon, Washington, and Texas. Fifty-three (38%) of these patients were hospitalized, including 24 (17%) who were admitted to intensive care units (ICUs); nine (5%) patients died. Ad14 isolates from all four states were identical by sequence data from the full hexon and fiber genes. However, the isolates were distinct from the Ad14 reference strain from 1955, suggesting the emergence and spread of a new Ad14 variant in the United States. No epidemiologic evidence of direct transmission linking the New York case or any of the clusters was identified. This report summarizes the investigation of these Ad14 cases by state and city health authorities, the U.S. Air Force, and CDC. State and local public health departments should be alert to the possibility of outbreaks caused by Ad14.
New York
In May 2006, a fatal case of Ad14 illness occurred in New York City in an infant girl aged 12 days. The infant was born after a full-term pregnancy and uncomplicated delivery. She was found dead in bed, where she had been sleeping. The infant had been examined 3 days after birth and noted to have lost weight but was otherwise healthy. The next week she had decreased tears with crying, suggesting early dehydration. Physical activity and feeding progressively decreased during the week before her death.
Postmortem tracheal and gastric swabs from the infant were sent to the Wadsworth Center laboratory of the New York State Department of Health, where adenovirus was detected by polymerase chain reaction (PCR). Adenovirus also was isolated by culture, confirmed by immunofluorescence assay (IFA), and typed as Ad14 by antibody neutralization assay. Analysis at CDC identified the same unique genetic sequences in this isolate as were later identified in the Ad14 isolates from the three 2007 clusters.
Autopsy and histologic findings at the Office of the Chief Medical Examiner in New York City included presence in the lung of chronic inflammatory cells with intranuclear inclusions, consistent with adenoviral bronchiolitis and acute respiratory distress syndrome. Investigation by the New York City Department of Health and Mental Hygiene has not identified any other local cases of Ad14 illness.
Oregon
In early April 2007, a clinician alerted the Oregon Public Health Division (OPHD) regarding multiple patients at a single hospital who had been admitted with a diagnosis of severe pneumonia during March 3-April 6. A total of 17 specimens were obtained from patients; 15 (88%) yielded isolates that were identified by CDC as Ad14. Through retrospective examination of laboratory reports from the three clinical laboratories in the state that have virology capacity and the Oregon State Public Health Laboratory (OSPHL), OPHD identified 68 persons who tested positive (by culture, PCR, or IFA) for adenovirus during November 1, 2006 -April 30, 2007 . Isolates from 50 (74%) of these patients were available for further adenovirus typing at either CDC or OSPHL. Of the 50 patient isolates, 31 (62%) were identified as Ad14, and 15 (30%) were identified as another adenovirus type ( Figure) ; four (8%) did not test positive for adenovirus.
Among 30 Ad14 patients (i.e., all but one) whose medical charts were reviewed, 22 (73%) were male; median age was 53.4 years (range: 2 weeks-82 years). Five cases (17%) occurred in patients aged <5 years, and the remaining 20 (83%) occurred in patients aged >18 years. Twenty-two patients (73%) required hospitalization, sixteen (53%) required intensive care, and seven (23%) died, all from severe pneumonia. Median age of the patients who died was 63.6 years; five (71%) were male. One death occurred in an infant aged 1 month. Of the 30 Ad14 cases with patient residence information available, 28 (93%) occurred in residents of seven Oregon counties, and two cases occurred in residents of two Washington counties. No link was identified in hospitals or the community to explain transmission of Ad14 from one patient to another.
In comparison with the Ad14 patients, among the 12 adenovirus non-type 14 patients (i.e., all but three) whose medical charts were reviewed, nine (75%) were male. Median age was 1.1 years, and 11 (92%) patients were aged <5 years. Two (17%) adenovirus non-type14 patients required hospitalization; no ICU admissions or deaths were reported in this group. 
Washington
On May 16, 2007, the Tacoma-Pierce County Health Department notified the Washington State Department of Health (WADOH) of four residents housed in one unit of a residential-care facility who had been hospitalized recently for pneumonia of unknown etiology. The patients were aged 40-62 years; three of the four were female. One patient had acquired immunodeficiency syndrome (AIDS); the three others had chronic obstructive pulmonary disease. All four were smokers.
The patients had initial symptoms of cough, fever, or shortness of breath during April 22- May 8, 2007 . Three patients required intensive care and mechanical ventilation for severe pneumonia. After 8 days of hospitalization, the patient with AIDS died; the other patients recovered. Respiratory specimens from all four patients tested positive for adenovirus by PCR at the WADOH laboratory; isolates were available from three patients, and all three isolates were identified as Ad14 by CDC. Ad14 had last been identified in an isolate from a patient from Washington in May 2006, marking the first identification of Ad14 in the state since 2004. Active surveillance among facility residents and staff did not identify any other cases of Ad14 illness.
Texas
Since February 2007, an outbreak of cases of febrile respiratory infection* associated with adenovirus infection has been reported among basic military trainees at Lackland Air Force Base (LAFB). During an initial investigation, conducted from February 3 to June 23, out of 423 respiratory specimens collected and tested, 268 (63%) tested positive for adenovirus; 118 (44%) of the 268 were serotyped, and 106 (90%) of those serotyped were Ad14. Before this outbreak, the only identification of an Ad14 isolate at LAFB occurred in May 2006 (1) .
During February 3-June 23, 2007, a total of 27 patients were hospitalized with pneumonia (median hospitalization: 3 days), including five who required admission to the ICU. One ICU patient required extracorporeal membrane oxygenation for approximately 3 weeks and ultimately died. All 16 hospitalized patients from whom throat swabs were collected, including the five patients admitted to the ICU, tested positive for Ad14.
Fifteen of these hospitalized patients tested negative for other respiratory pathogens, and one patient had a sputum culture that was positive for Haemophilus influenzae.
All health-care workers from hospital units where trainees had been admitted were offered testing for Ad14, regardless of history of respiratory illness. Of 218 healthcare workers tested by PCR, six (3%) were positive for Ad14; five of the six reported direct contact with hospitalized Ad14 patients.
Prevention measures implemented during the outbreak included increasing the number of hand-sanitizing stations, widespread sanitizing of surfaces and equipment with appropriate disinfectants, increasing awareness of Ad14 among trainees and staff members, and taking contact and droplet precautions for hospitalized patients with Ad14. Beginning on May 26, trainees with febrile respiratory illness were confined to one dormitory and both patients and staff members were required to wear surgical masks.
Cases reported postinvestigation. Since the investigation, new cases of febrile respiratory illness have continued to occur at LAFB, but the weekly incidence has declined from a peak of 74 cases with onset during the week of May 27-June 2, to 55 cases with onset during the week of September 23-29 (the most recent period for which data were available). In addition, during March-September 2007, three other military bases in Texas that received trainees from LAFB reported a total of 220 cases of Ad14 illness (Air Force Institute for Operational Health, personal communication, 2007). However, whether Ad14 spread from LAFB to these three bases has not been determined. Ad14 also was detected in April in an eye culture from an outpatient in the surrounding community who had respiratory symptoms and conjunctivitis. No link between this case and the LAFB cases was identified. (8) . Ten of the 17 isolates (60%) were collected from three military bases (8) . Despite this surveillance, adenovirus infections often go undetected, because few laboratories routinely test for adenovirus and even fewer do serotyping. Wider circulation of Ad14 might have occurred in recent years and might still be occurring.
Further work is needed to understand the natural history of Ad14, risk factors for severe Ad14 disease, and how Ad14 transmission can be prevented effectively. Vaccines against adenovirus serotypes four and seven (i.e., Ad4 and Ad7) were used among military recruits during 1971-1999, before vaccines were no longer available. Adenoviral disease among U.S. military recruits subsequently increased (9) . Ad4 and Ad7 oral vaccines have been redeveloped and are being evaluated in clinical trials. Work is ongoing to determine whether the new Ad4 and Ad7 vaccines will protect against Ad14 infection. Management of adenoviral infections is largely supportive. A number of antiviral drugs, including ribavirin, vidarabine, and cidofovir, have been used to treat adenoviral infections such as Ad14, but none have shown definitive efficacy against adenoviruses (2) .
Control of adenovirus outbreaks can be challenging because these viruses can be shed in both respiratory secretions and feces and can persist for weeks on environmental surfaces. Guidelines for the care of patients with pneumonia (10) should be followed in cases of suspected adenoviral pneumonia.
Clinicians with questions related to testing of patients for adenovirus or Ad14 infection should contact their state health departments, which can provide assistance. State health departments and military facilities should contact CDC to report unusual clusters of severe adenoviral disease or cases of Ad14 or to obtain additional information regarding laboratory testing. Diabetes is a chronic disease with a U.S. prevalence of 18 cases per 10,000 youths aged <20 years (1) . With proper management and access to care, morbidity and mortality from diabetes are preventable, particularly in the pediatric population (2, 3) . Although diabetes is more common among non-Hispanic white youths, some studies report higher death rates among racial/ethnic minorities and among those in lower socioeconomic strata (3, 4 Further study is needed to discern the specific reasons for increased diabetes mortality in black youths. Better identification and management of the disease among youths, especially among black youths, might help decrease racial disparities and prevent deaths from diabetes.
To obtain stable estimates, diabetes death rates were calculated as 2-year annual averages for the period 1979-2004 for all persons aged 1-19 years and for blacks and whites in that age group. The numbers of diabetes deaths in other racial groups were too small to obtain reliable estimates, and Hispanic origin was not recorded on death certificates in all states until 1997. Infants aged <1 year were excluded because of differences in estimating mortality rates among infants in the neonatal and postneonatal period, compared with children aged >1 year. Numbers of deaths for which diabetes was the underlying cause* and population estimates for calculation of rates were obtained from the CDC WONDER online database compressed mortality file of the National Vital Statistics System (NVSS). International Classification of Diseases, Ninth Revision (ICD-9) † cause-ofdeath codes for diabetes mellitus (250) were used for 1979-1998, and International Classification of Diseases, Tenth Revision (ICD-10) § codes (E10-E14) were used for 1999-2004. Trends over time for 2-year annual averages were assessed using Hudson's algorithm in statistical software (6) to test whether trends were statistically significant (p<0.05) and to identify points (i.e., joinpoints) where trends changed during the study period. Previous analyses of the comparability of underlying cause-of-death classification between deaths coded using the ICD-9 system and those coded using the ICD-10 system have indicated that the change from ICD-9 to ICD-10 in 1999 likely had little impact on the proportion of deaths attributed to diabetes for the age group included in this study and for blacks and whites of all ages (CDC, unpublished data, 2004). ¶ Therefore, the period 1979-2004 was analyzed as a continuous trend. Rate ratios and 95% confidence intervals (CIs) for death rates of blacks compared with death rates of whites were calculated for each 2-year interval. Age-adjusted rates were examined and determined to be identical to crude rates. Thus, crude rates are presented in this report.
During implementation of new ICD-10 cause-of-death coding procedures began in 1999, the coding change is probably not the cause of the increase in diabetes deaths among black youths. Diabetes mortality among adults traditionally includes deaths for which diabetes was a contributing cause and those for which it was an underlying cause. For children, however, diabetes deaths are less likely to be from consequences of long-standing diabetes (e.g., cardiovascular and cerebrovascular disease) and more likely to be from direct complications (e.g., ketoacidosis and hypoglycemia) and to occur among persons with short duration of the disease (3, 7) . Therefore, this analysis included only underlying cause of death.
The factors contributing to racial disparities in pediatric and adolescent diabetes mortality during 1979-2004 likely are complex. Possible explanations include differences in access to and use of health-care services (8) and differences in the quality of disease education and care (3). More in-depth analyses are needed to assess these factors and the effect of recent increases in type 2 diabetes among children in racial/ethnic minority groups (9) .
The findings in this report are subject to at least three limitations. First, deaths attributable to diabetes cannot be examined by the specific type of diabetes because of the small number of these deaths and the high percentage of pediatric and adolescent diabetes deaths unclassified by type (76% in 2004). Second, the use of NVSS data precludes adjustment of data comparing racial groups for potential confounders, such as socioeconomic status or healthinsurance status. Finally, this study could not determine the cause of the statistically significant increase in diabetes mortality among black youths during 1998-2004. This increase might be attributed to random variation, given the rarity of diabetes deaths in the 1-19 years age group and the limited period during which the increase was observed. However, further evaluation of this trend is needed.
These findings demonstrate consistent racial disparities in diabetes mortality among youths in the United States during 1979-2004, although, in absolute numbers of deaths, the differences are not sizeable because of the rare occurrence of diabetes-related deaths in this population (annual average of 89 deaths during [2003] [2004] . However, these disparities remain a public health concern for two reasons. First, diabetes deaths among young persons are predominantly attributed to acute complications, such as ketoacidosis, and thus are preventable (3). Metabolic decompensation from acute diabetes complications is easy to recognize in young persons and requires quality care of high urgency but low technology (3). Second, incidence of type 2 diabetes in children and adolescents is increasing (9) . Education of health professionals who care for youths, especially black youths, and improved public awareness of increasing diabetes incidence, particularly among minority racial/ethnic groups, might improve identification of diabetes in black and other minority children and adolescents. These practices might lead to improved management of the disease and decreased morbidity and mortality among youths.
Progress Toward Poliomyelitis Eradication -India, January 2006-September 2007
India is one of four countries where wild poliovirus (WPV) transmission has never been interrupted (the others are Afghanistan, Nigeria, and Pakistan) (1) . An outbreak of poliomyelitis cases caused by WPV type 1 (WPV1) occurred in India in 2006, primarily in the northern states of Uttar Pradesh and Bihar, where polio remains endemic. This outbreak resulted in the greatest annual number of cases of poliomyelitis in India since 2002. In response, the Government of India and its partners implemented additional vaccination measures based on recommendations from the India Expert Advisory Group on Polio Eradication. These measures focused predominantly on use of monovalent oral poliovirus vaccine type 1 (mOPV1),* which has higher efficacy against WPV1 than trivalent OPV (tOPV) (2,3). 
Acute Flaccid Paralysis (AFP) Surveillance
AFP surveillance † is fundamental to monitoring progress toward polio eradication; surveillance quality is monitored according to World Health Organization (WHO) operational targets. § The national nonpolio AFP rate (i.e., the number of nonpolio AFP cases per 100,000 population aged <15 years) was similar during January-December 2006 (7.35 cases) and January-September 2007 (7.83 cases). In 2006 and 2007, nonpolio AFP rates were highest in Uttar Pradesh (15.80 cases and 15.32 cases, respectively) and Bihar (19.00 cases and 20.97 cases, respectively). Adequate stoolspecimen collection nationally was 82% in 2006 and 85% during January-September 2007.
* mOPV contains polio vaccine virus of either type 1 or type 3 only. mOPV provides greater WPV type-specific immunity per dose than tOPV. † The AFP surveillance system tracks any case of AFP in a child aged <15 years or any case of paralytic illness in a person of any age when polio is suspected. Additional information regarding AFP surveillance is available at http://www. polioeradication.org/content/fixed/afp.shtml. § The current WHO operational target for countries with endemic polio transmission is a nonpolio AFP rate of at least two cases per 100,000 population aged <15 years and adequate stool-specimen collection from >80% of AFP cases, in which two specimens are collected >24 hours apart, both within 14 days of paralysis onset, and shipped on ice or frozen ice packs to a WHO-accredited laboratory, arriving in good condition. When operational targets for nonpolio AFP incidence and specimen collection are reached or exceeded in all areas, little
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Virologic testing of stool specimens from AFP patients in India is conducted at eight laboratories, all of which are accredited by WHO as part of the Global Polio Laboratory Network (5 
Immunization Activities
Reported routine vaccination coverage of infants with 3 doses of OPV was 68% in India in 2006 (6) . In Bihar and Uttar Pradesh, coverage was lower (48% and 44%, respec- dose of OPV is administered to all children aged <5 years, regardless of vaccination history. The geographic extent of campaigns (national versus subnational) is determined by analysis of surveillance data. OPV is administered at fixed sites, by mobile teams during house-to-house visits, and by teams at transit points (e.g., train stations or markets). † † SIA quality is defined by the percentage of houses detected, after a vaccination activity has been completed, with a child who might not have been vaccinated. § § Moradabad is a densely populated district in Uttar Pradesh with an underserved population (i.e., a population with low socioeconomic standing, marginalized status, and poor sanitation).
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Development Dept, WHO Editorial Note: India has continued to make progress towards polio eradication despite a WPV1 outbreak in 2006 and an ongoing WPV3 outbreak in 2007. Based on recommendations of the Global Advisory Committee on Polio Eradication and the India Expert Advisory Group on Polio Eradication, India has prioritized elimination of WPV1 because this virus type has a greater likelihood of causing paralytic disease, has been responsible for >90% of polio cases in the country during the past 5 years, and has been the source for reinfection of six polio-free countries (Angola, Bangladesh, Democratic Republic of the Congo, Myanmar, Namibia, and Nepal). Consequently, the intensified use of mOPV1 during frequent, large-scale SIAs coupled with improvements in the quality and consistency of SIA coverage has been critical to substantially curtailing the outbreak of WPV1. For the first time, this strategy has led to record low numbers of WPV1 cases in the areas that previously had the highest incidence. The limited number of WPV1 cases in western Uttar Pradesh and the continued decline of WPV1 incidence throughout the peak transmis- Table) . A total of 1,803 (55%) cases for which such data were available occurred in males; median age of patients was 51 years (range: 1 month-97 years). Dates of illness onset ranged from January 8 to November 6; a total of 93 cases were fatal. 
Notice to Readers

National Family History DayThanksgiving Day
Beginning in 2004, Thanksgiving Day was declared National Family History Day by the U.S. Surgeon General to encourage families to discuss their health histories. Although 96% of persons in the United States believe that knowing their family history is important, only one third of them have ever tried to gather and write down their family health history (1) .
The Office of the Surgeon General, in collaboration with several agencies in the U.S. Department of Health and Human Services, developed a tool for recording family health information (available at https://familyhistory.hhs.gov). In addition, in 2002, CDC's National Office of Public Health Genomics (NOPHG) launched the Family History Public Health Initiative, which collaborates with government agencies, public health organizations, universities, and the private sector to assess and promote the use of family history for improving the health of the U.S. population. Family history resources and tools are available from NOPHG at http://www.cdc.gov/genomics/public/famhist.htm.
To extend this initiative to children, CDC's National Center on Birth Defects and Developmental Disabilities sponsored a meeting in 2006 to assess the use of family history information in pediatric primary care and to evaluate medical conditions that could serve as models for using this information in pediatric and public health settings (2 In 2006, among Hispanic, non-Hispanic black, and non-Hispanic white adults, women were more likely than men to have asthma. Overall, Hispanics were less likely than non-Hispanic whites and non-Hispanic blacks to have asthma. Guam  58  3  207  488  769  -0  0  ---0  0  --Puerto Rico  104  131  543  6,493 4,414 -6  18  313  269  66  41  204  1,819  2,034  2  0  7  47  42  Maine§   5  3  10  173  164  -2  8  104  113  -0  4  13  18  Massachusetts  -10  29  521  554  39  51  96  2,249  2,095  -2  6  74  68  New Hampshire  1  0  3  24  21  2  2  8  131  166  -0  2  15  11  Rhode Island§   1  0  15  73  100  6  8  18  359  444  -0  10  7  4  Vermont§   -3  9  149  167  -1  5  48  63  -0  1 -0  1  7  3  -0  1  2  23  -0  1  1  3  California  -2  9  114  73  -2  7  106  141  -3  10  146  164  Hawaii  N  0  0  N  N  -0  1  2  8  -0  2  8  8  Oregon§   -0  1  3  6  1  0  3  14  11  -0  3  30  37  Washington  -0  8  3  -3  0  43  25  --0  43 21 - -20  226  825  762  -1  27  73  890  1  1  168  172  110  Arkansas†   -2  17  130  85  -0  5  28  26  -0  53  90  49  Louisiana  -0  1  14  24  -0  1  -6  -0  1  2  4  Oklahoma  -0  36  6  19  -0  22  45  58  -0  108  47  28  Texas†   -17  174  675  634  -0  20  -800  1  0  7  33  29   Mountain  12  22  61  951  2,270  1  3  14  205  206  -0  4  33  46  Arizona  -4  13  179  466  1  2  12  144  133  -0  1  7  11  Colorado  -6  17  230  669  -0  0  ---0  2 -2  14  112  96  -0  3  11  25  -0  1  2  2  Washington  4  2  377 -7  15  276  372  -1  11  79  100  -1  6  72  113  Washington  16  11  625  580  2  6  1  162  126  -7  1  170 -0  2  10  -1  1  4  53  61  Texas§   -0  0  ---0  0  --30  21  39  1,036  958   Mountain  -1  6  55  83  -0  3  18  35  3  8  22  326  426  Arizona  -0  0  ---0  0  --2  3  22  149  166  Colorado  -0  0  ---0  0  --1  1  5  32  60  Idaho§   N  0  0  N  N  -0  0  ---0  1  1  3  Montana§   -0  0  ---0  0  ---0  2  3  1  Nevada§   -0  3  18  16  -0  2  5  2  -2  6  87  116  New Mexico§   -0  0  ---0  0  ---1  7  3 8  6 5  Utah  -0  6  23  35  -0  3  11  23  -0  2  13  15  Wyoming§   -0  2  1 4  3 2  -0  1  2  1 0  -0  1  3  -Pacific  -0  0  ---0  1  3  -1  39  58  1,632  1,799  Alaska  -0  0  ---0  0  ---0  1  7  10  California  N  0  0  N  N  -0  0  ---36  55  1,488  1,598  Hawaii  -0  0  ---0  1  3  --0  2  7 
SOURCE:
- - - 1 1 - 1 1 SARS-CoV §, § § § - - - - - - 8 N Smallpox § - - - - - - - - Streptococcal- - - 1 3 1 N N Vibriosis (noncholera Vibrio species infections) § 3 3 2 3 2 N N N N N N Y (1), FL (2) Yellow fever - - - - - - - 1N 0 0 N N - 0 0 - - American Samoa U 0 32 U U U 0 0 U U U 0 0 U U C.N.M.I. U - - U U U - - U U U - - U UN 0 0 N N N 0 0 N N U.S. Virgin Islands U 3 7 U U U 0 0 U U U 0 0 U UAmerican Samoa U 0 0 U U U 0 2 U U U 0 0 U U C.N.M.I. U - - U U U - - U U U - - U U Guam - 0 0 - - 6 1American Samoa U 0 0 U U U 0 0 U U U 0 0 U U C.N.M.I. U - - U U U - - U U U - - U U Guam - 0 0 - - - 0 0 - - - 0 0 - - PuertoAmerican Samoa U 0 0 U U U 0 0 U U U 0 0 - - C.N.M.I. U - - U U U - - U U U - - - - Guam - 0 0 - - - 0 0 - - - 0 0 - - Puerto Rico N 0 0 N N - 0 1 3 2 - 0 1 6 6 U.S. Virgin Islands U 0 0 U U U 0 0 U U U 0 0 - -
